<DOC>
	<DOC>NCT02354534</DOC>
	<brief_summary>This phase I research protocol is designed to assess immunogenicity and clinical endpoints in patients with HPV16 CIN2/3. The protocol tests the use of artesunate in suppository formulation applied intravaginally in patients with cervical dysplasia (CIN2/3). The primary endpoint is to determine and evaluate the safety, tolerability, and feasibility of intravaginal administration of artesunate in health women with CIN2/3.</brief_summary>
	<brief_title>Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3)</brief_title>
	<detailed_description>Phase I open-label dose escalation study of intravaginal artesunate, formulated in suppositories, in adult females with biopsy-confirmed CIN2/3. Thirty (30) subjects will undergo up to a total of three cycles of intravaginal artesunate. The first cycle will be initiated on Day 0, the second at Week 4, and the third and final cycle at week 8.</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma in Situ</mesh_term>
	<mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
	<mesh_term>Uterine Cervical Dysplasia</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<criteria>≥ 18 years Capable of informed consent HPVpositive by DNA test Histologically confirmed CIN2, CIN3, or CIN2/3 Body weight ≥ 50 kg Immune competent Pregnant and nursing women HIV seropositive Active autoimmune disease Taking immunosuppressive medication Evidence of concurrent adenocarcinoma in situ Concurrent malignancy except for nonmelanoma skin lesions</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>cervical dysplasia</keyword>
	<keyword>HPV</keyword>
	<keyword>Treatment</keyword>
	<keyword>preinvasive</keyword>
	<keyword>cervix</keyword>
	<keyword>vaginal suppository</keyword>
	<keyword>Johns Hopkins</keyword>
	<keyword>Cornelia Trimble</keyword>
	<keyword>abnormal pap</keyword>
	<keyword>CIN</keyword>
</DOC>